RENB

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Renovaro Biosciences Inc

NASDAQ | RENB

1.42

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 30, 2025)

$33.82M

Market Cap

-

P/E Ratio

-10.8

EPS

$21.00

52 Week High

$1.21

52 Week Low

HEALTHCARE

Sector

RENB Chart

Recent Chart
Price Action

RENB Technicals

Tags:

RENB Earnings

Yearly Income Statement (As of Jun 30, 2025)

Field Value (USD)
Gross Profit -$122K
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$82M
Selling General And Administrative $24M
Research And Development $2.7M
Operating Expenses $82M
Investment Income Net -
Net Interest Income -$609K
Interest Income $116K
Interest Expense $1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $122K
Income Before Tax -$81M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$178M
Comprehensive Income Net Of Tax -
Ebit -$82M
Ebitda -$82M
Net Income -$81M

Revenue & Profitability

Earnings Performance

RENB Financials

yearly Balance Sheet (As of Jun 30, 2025)

Field Value (USD)
Total Assets $163M
Total Current Assets $2M
Cash And Cash Equivalents At Carrying Value $220K
Cash And Short Term Investments $220K
Inventory -
Current Net Receivables $1.1M
Total Non Current Assets $161M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $30K
Intangible Assets Excluding Goodwill $30K
Goodwill $159M
Investments -
Long Term Investments -
Short Term Investments $388K
Other Current Assets $669K
Other Non Current Assets -
Total Liabilities $31M
Total Current Liabilities $30M
Current Accounts Payable $9.4M
Deferred Revenue -
Current Debt -
Short Term Debt $2.9M
Total Non Current Liabilities $842K
Capital Lease Obligations $738K
Long Term Debt -
Current Long Term Debt $9.4M
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.8M
Other Current Liabilities $18M
Other Non Current Liabilities -
Total Shareholder Equity $132M
Treasury Stock -
Retained Earnings -$332M
Common Stock $16K
Common Stock Shares Outstanding $9.6M

yearly Cash Flow (As of Jun 30, 2025)

Field Value (USD)
Operating Cashflow -$11M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $122K
Capital Expenditures $70K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$1.3M
Cashflow From Financing $11M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$81M

yearly Income Statement (As of Jun 30, 2025)

Field Value (USD)
Gross Profit -$122K
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$82M
Selling General And Administrative $24M
Research And Development $2.7M
Operating Expenses $82M
Investment Income Net -
Net Interest Income -$609K
Interest Income $116K
Interest Expense $1M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $122K
Income Before Tax -$81M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$178M
Comprehensive Income Net Of Tax -
Ebit -$82M
Ebitda -$82M
Net Income -$81M

RENB Profile

Renovaro Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Renovaro Biosciences Inc. is a pre-clinical stage biotechnology company based in Los Angeles, California, focusing on the innovative research and development of therapeutic solutions for critical health challenges, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and various types of cancer. With a commitment to advancing the biotechnology landscape, Renovaro aims to leverage its proprietary technologies to deliver novel pharmaceutical and biological products. As it progresses through its development pipeline, the company represents a unique investment opportunity in the evolving field of targeted disease management.

YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
WGRX
+9.03%
$0.40
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
SGBX
+29.82%
$2.96
RMBL
+60.50%
$3.21
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
SCWO
+32.07%
$0.48
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
VALE
-0.52%
$11.46
HOOD
+5.58%
$134.33
DNUT
+1.98%
$4.11
LUMN
+10.65%
$7.79
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
NAKA
+10.41%
$0.79
KDLY
+10.41%
$0.79
YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
WGRX
+9.03%
$0.40
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
SGBX
+29.82%
$2.96
RMBL
+60.50%
$3.21
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
SCWO
+32.07%
$0.48
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
VALE
-0.52%
$11.46
HOOD
+5.58%
$134.33
DNUT
+1.98%
$4.11
LUMN
+10.65%
$7.79
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
NAKA
+10.41%
$0.79
KDLY
+10.41%
$0.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.